MA32545B1 - Composition - Google Patents

Composition

Info

Publication number
MA32545B1
MA32545B1 MA33592A MA33592A MA32545B1 MA 32545 B1 MA32545 B1 MA 32545B1 MA 33592 A MA33592 A MA 33592A MA 33592 A MA33592 A MA 33592A MA 32545 B1 MA32545 B1 MA 32545B1
Authority
MA
Morocco
Prior art keywords
composition
relates
iii
preparing
polymer component
Prior art date
Application number
MA33592A
Other languages
Arabic (ar)
English (en)
Inventor
Andrew Naylor
Andrew Lester Lewis
Lisbeth Illum
Original Assignee
Critical Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39722152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32545(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Critical Pharmaceuticals Ltd filed Critical Critical Pharmaceuticals Ltd
Publication of MA32545B1 publication Critical patent/MA32545B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition comprenant (i) une hormone somatotrophique, un composant polymère biodégradable, et (iii) un modificateur de libération. L'invention concerne également un procédé permettant de préparer et d'utiliser une telle composition.
MA33592A 2008-07-11 2011-02-08 Composition MA32545B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0812740.9A GB0812740D0 (en) 2008-07-11 2008-07-11 Composition
PCT/GB2009/001727 WO2010004299A2 (fr) 2008-07-11 2009-07-10 Composition

Publications (1)

Publication Number Publication Date
MA32545B1 true MA32545B1 (fr) 2011-08-01

Family

ID=39722152

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33592A MA32545B1 (fr) 2008-07-11 2011-02-08 Composition

Country Status (18)

Country Link
US (1) US20110257097A1 (fr)
EP (1) EP2317979A2 (fr)
JP (1) JP2011527329A (fr)
KR (1) KR20110040892A (fr)
CN (1) CN102131498A (fr)
AU (1) AU2009269818A1 (fr)
BR (1) BRPI0915857A2 (fr)
CA (1) CA2730325A1 (fr)
CL (1) CL2011000063A1 (fr)
CO (1) CO6331422A2 (fr)
CR (1) CR20110078A (fr)
EA (1) EA201170180A1 (fr)
GB (2) GB0812740D0 (fr)
IL (1) IL210555A0 (fr)
MA (1) MA32545B1 (fr)
MX (1) MX2011000259A (fr)
WO (1) WO2010004299A2 (fr)
ZA (1) ZA201101053B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
EP2165919A1 (fr) 2008-09-19 2010-03-24 Sika Technology AG Structure renforcée pour véhicules
CN101972212A (zh) * 2010-10-29 2011-02-16 华侨大学 超临界流体技术制备核壳型复合微球的方法
KR20160038801A (ko) * 2014-09-29 2016-04-07 (주)엘지하우시스 중합체 분말 및 이의 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100210509B1 (ko) * 1996-01-10 1999-07-15 성재갑 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
US6444223B1 (en) * 1999-05-28 2002-09-03 Alkermes Controlled Therapeutics, Inc. Method of producing submicron particles of a labile agent and use thereof
KR20010002589A (ko) * 1999-06-16 2001-01-15 김윤 생리활성물질 함유 생분해성 고분자 마이크로스피어의 제조방법
KR100622996B1 (ko) * 2005-03-03 2006-09-14 한국과학기술원 약물이 봉입된 비다공성 고분자 미립 담체 및 이의 제조방법
JP5647788B2 (ja) * 2006-10-11 2015-01-07 トルマー セラピューティクス， インコーポレイテッド． 超臨界流体抽出による低バースト特性の生分解性ポリエステルの調製

Also Published As

Publication number Publication date
US20110257097A1 (en) 2011-10-20
CL2011000063A1 (es) 2011-09-23
CA2730325A1 (fr) 2010-01-14
EA201170180A1 (ru) 2011-08-30
CN102131498A (zh) 2011-07-20
CR20110078A (es) 2011-05-03
WO2010004299A2 (fr) 2010-01-14
KR20110040892A (ko) 2011-04-20
JP2011527329A (ja) 2011-10-27
ZA201101053B (en) 2012-07-25
EP2317979A2 (fr) 2011-05-11
GB201102015D0 (en) 2011-03-23
AU2009269818A1 (en) 2010-01-14
BRPI0915857A2 (pt) 2015-11-03
GB2474001A (en) 2011-03-30
GB0812740D0 (en) 2008-08-20
CO6331422A2 (es) 2011-10-20
WO2010004299A3 (fr) 2010-11-11
IL210555A0 (en) 2011-03-31
MX2011000259A (es) 2011-04-05

Similar Documents

Publication Publication Date Title
MY161620A (en) Oral care formulations that enhance amount of soluble zinc
MA29788B1 (fr) Combinaisons comprenant un inhibiteur des recepteurs vegf
TW200714283A (en) Method and composition for treating peripheral vascular diseases
WO2007109810A3 (fr) Procedes de preparation de composes contenant de l'imidazole
WO2007106469A3 (fr) Derives bicycliques de l'acide carboxylique utiles dans le traitement de troubles metaboliques
TW200603728A (en) A method for treating plants or plant parts
WO2007035629A3 (fr) Inhibiteurs de dipeptidylpeptidase
MA29816B1 (fr) Composes de benzimidazole thiophene
UA106507C2 (uk) Кон'югати димерів піроло[1,4]бензодіазепіну як протираковий засіб
WO2006099357A3 (fr) Composition polymerisable comprenant un constituant organique de faible poids moleculaire
MX2010009654A (es) Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos.
WO2005079756A3 (fr) Methodes et compositions de traitement de troubles psychiatriques
NZ593874A (en) Nalmefene hydrochloride dihydrate
WO2008011071A3 (fr) Interactions des voies de signaux hedgehog et du récepteur x hépatique
MA33198B1 (fr) Anticorps anti-her di-spécifiques
DE602006012694D1 (de) Benzimidazolthiophenverbindungen als plk-modulatoren
TWI267158B (en) Elongated features for improved alignment process integration
DE602006013151D1 (de) Verfahren zur herstellung von polymermaleimiden
MX2010000372A (es) Composiciones polimericas modificadas, proceso de modificacion y agentes generadores de radicales libres.
MX2010007392A (es) Antagonistas de trpa1.
EP2428507A3 (fr) Ligands du récepteur cannabinoïde
WO2012078546A3 (fr) Compositions et méthodes de stabilisation d'ingrédients au moyen de composés de 2,4-pentanediones
MX2010007391A (es) Antagonistas de trpa1.
MA32545B1 (fr) Composition
WO2010042780A3 (fr) Procédés et compositions pour traiter un état de mal épileptique et les crises d'épilepsie causant un état de mal épileptique